Brought to you by 
Orphazyme enters €9mm debt financing with Kreos Capital
06 Sep 2019
Executive Summary
Rare disease-focused Orphazyme AS entered into a €9mm ($10mm) loan agreement with Kreos Capital. The structured debt facility has a term of 42 months and carries an annual fixed interest rate of 9.75%. The first 12 months are interest-only, while the remaining 30 months require equal installments of principal and interest. Orphazyme plans to draw down the loan on September 1, 2019. The company will use the funding to file for regulatory approvals (expected in H1 2020) of its arimoclomol for Niemann Pick Type-C in the US and Europe, and for commercial planning.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Nonconvertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Orphazyme enters €9mm debt financing with Kreos Capital
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice